Abstract
Using non-myeloablative conditioning, allogeneic hematopoietic stem cell transplantation (HSCT) was conducted in 43 ALL patients in a CR2. The median age of the patients was 19 years. Patients received oral busulfan 4 mg/kg/day for 2 days; i.v. cyclophosphamide 350 mg/m2/day for 3 days; and i.v. fludarabine 30 mg/m2/day for 3 days. Oral cyclosporin A 4 mg/kg was started and methotrexate 5 mg/m2 was delivered on days 1, 3, 5 and 11. The median CD34+ cell dose received was 5.0 × 106/kg. The medium time to achieve a granulocyte count above 0.5 × 109/l was 14 days. Thirteen patients were alive 30–1050 days after the HSCT. The 3-year overall survival rate was 30%. Ten patients (23%) developed acute GVHD, whereas eight patients (18.6%) developed chronic GVHD. Thirty patients died between days 47 and 1050 after the HSCT, most of them (70%) because of an ALL relapse. One hundred-day mortality was 15%, whereas transplant-related mortality was 21%. These results are inferior to those obtained using the same allografting method in other leukemias, probably as a consequence of poor susceptibility to the graft-versus-leukemia effect of the ALL cells beyond first remission as compared with other hematological malignancies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Larson RA . The US Trials in adult acute lymphoblastic leukemia. Ann Hematol 2004; 83: S127–S128.
Annino L, Vegna ML, Camera A, Specchia G, Visan G, Fioritoni G et al. Treatment of acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002; 99: 863–871.
Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N et al. Outcome of treatment in adults with acute lymphoblastic leukemia : analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075–4086.
Pui CH, Evans WE . Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166–178.
Hunault M, Horousseau JL, Delain M, Truchan-Graczy KM, Cahn JY, Witz F et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS Trial. Blood 2004; 104: 3028–3037.
MC Sweeney PA, Niderwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematological malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effect. Blood 2001; 97: 3390–3399.
Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD . Autologous peripheral hematopoietic stem cell transplantation restores hemopoietic function following marrow ablative therapy. Blood 1998; 71: 723–727.
Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE . Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transplant 2000; 25: 131–133.
Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O . Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 2002; 87: 894–896.
Ruiz-Argüelles A . Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin 1992; 50: 735–743.
Ruiz-Argüelles A, Orfao A . Caracterización y evaluación de células totipotenciales en sangre periférica y médula ósea. In: Ruiz-Argüelles GJ, San-Miguel JF (eds). Actualización en Leucemias. Editorial Médica Panamericana. México City, 1996, pp 79–82.
Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.
Yam P, Petz L, Knowlton R, Wallace R, Stock A, deLange G et al. Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation 1987; 43: 399–407.
Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Pérez-Romano B, Ruiz-Argüelles A, Ramírez-Cisneros F et al. Assessment of residual disease in acute leukemia by means of polymerase chain reaction: a prospective study in a single institution. Rev Invest Clin Mex 2000; 52: 118–124.
Doney K, Hägglund H, Leisenring W, Chauncey T, Appelbaum FR, Storb R . Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2003; 9: 472–481.
Rowe JM, Buck G, Fielding A, Tallman MS, Burnett AK, Chopra R et al. In adults with standard-risk acute lymphoblastic leukemia (ALL) the greatest benefit is achieved from an allogeneic transplant in first complete remission (CR) and an autologous transplant is less effective than conventional consolidation/maintenance chemotherapy: final results of the international ALL trial (MRC UKALL XII/ECOG E2993). Blood (ASH Annual Meeting Abstracts) 2006; 108: 2.
Feig SA, Harris RE, Sather HN . Bone marrow transplantation versus chemotherapy for maintenance of second remission of childhood acute lymphoblastic leukemia: a study of the children's cancer group (CCG-1884). Med Pediatr Oncol 1997; 29: 534–540.
Boulad F, Steinherz P, Reys B, Heller G, Gillio AP, Small TN et al. Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. J Clin Oncol 1999; 17: 197–207.
Uderzo C, Valsecchi MG, Balduzzi A . Allogeneic bone marrow transplantation versus chemotherapy in high risk childhood acute lymphoblastic leukaemia in first remission. Associazione Italiana di ematologia ed oncologia pediatrica (AIEOP) and the gruppo Italiano trapianto di midollo osseo (GITMO). Br J Haematol 1997; 96: 387–394.
Henze G, Fengler R, Hartmann R . Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85): a relapse study of the BFM group. Blood 1991; 78: 1162–1172.
Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE . Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transplant 2000; 25: 131–133.
Ruiz-Argüelles GJ, Gómez-Almaguer D, Morales-Toquero A, Gutiérrez-Aguirre CH, Vela-Ojeda J, García-Ruiz-Esparza M et al. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 2005; 36: 1043–1047.
Uzunel M, Mattsson J, Jaksch M, Remberger M, Ringden O . The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood 2001; 98: 1982–1985.
Ringden O, Labopin M, Gluckman E . Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined witn methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1996; 18: 921–929.
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.
Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez Rangel JD, Vela-Ojeda J, Cantú-Rodríguez OG, Jaime-Pérez JC et al. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute leukemia eligible for conventional allografting: a prospective study. Leuk Lymphoma 2004; 45: 1191–1195.
Ruiz-Argüelles GJ . The Mexican approach to conduct allogeneic stem cell transplantation: breaking dogmata and facing the Matthew effect. Hematology 2005; 10 (Suppl 1): 154–160.
Ruiz-Argüelles GJ, Gómez-Almaguer D, Vela-Ojeda J, Morales-Toquero A, Gómez-Rangel JD, García-Ruiz-Esparza MA et al. Extramedullary leukemic relapses following hematopoietic stem cell transplantation with non-myeloablative conditioning. Int J Hematol 2005; 82: 262–265.
Gomez-Almaguer D . The simplification of the SCT procedures in developing countries has resulted in cost-lowering and availability to more patients. Int J Hematol 2002; 76 (Suppl 1): 380–382.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gutierrez-Aguirre, C., Gomez-Almaguer, D., Cantu-Rodríguez, O. et al. Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study. Bone Marrow Transplant 40, 535–539 (2007). https://doi.org/10.1038/sj.bmt.1705769
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705769
Keywords
This article is cited by
-
Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study
Bone Marrow Transplantation (2013)
-
Comparable outcomes of partially matched related and matched related allogeneic hematopoietic cell transplantation following reduced-intensity conditioning in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia
International Journal of Hematology (2013)
-
Stem cells in clinical practice: applications and warnings
Journal of Experimental & Clinical Cancer Research (2011)
-
Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method
Annals of Hematology (2010)
-
Allogeneic transplantation for ALL in adults
Bone Marrow Transplantation (2008)